\nDescription<\/td>\n | Treatment-Emergent Adverse Event Incidence of patients receiving intratumoral injection of PV-001-DV in combination with IV infusion of PV-001-DC<\/td>\n | Description<\/td>\n | Tumor response will be measured per investigator's assessment according to RECIST v1.1 and iRECIST<\/td>\n | Description<\/td>\n | The length of time during the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse, up to the end of the study<\/td>\n | Description<\/td>\n | Overall Survival is measured from the date of enrollment to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date, up to the end of the study<\/td>\n<\/tr>\n<\/table>\n<\/div>\n |